- Home
- SRPT
SRPT
Sarepta Therapeutics Inc. (DE)
as 07-26-2024 4:00pm EST
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 1997 |
| Target Price: | $187.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $55.25 - $173.25 | Next Earning Date: | 08-05-2024 |
| Revenue: | $1,403,300,000 | Revenue Growth: | 43.83% |
| Revenue Growth (this year): | 59.17% | Revenue Growth (next year): | 50.88% |
Stock Insider Trading Activity of Sarepta Therapeutics Inc. (DE) (SRPT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Arif Bilal | SRPT | Chief Tech Ops Officer | Jun 21 '24 | Sell | $163.23 | 3,898 | $636,270.54 | 17,363 | SEC Form 4 |
| Arif Bilal | SRPT | Chief Tech Ops Officer | Jun 21 '24 | Sell | $167.13 | 224 | $37,437.12 | 21,261 | SEC Form 4 |
| Arif Bilal | SRPT | Chief Tech Ops Officer | Jun 21 '24 | Sell | $166.10 | 700 | $116,270.00 | 21,485 | SEC Form 4 |
| Arif Bilal | SRPT | Chief Tech Ops Officer | Jun 21 '24 | Sell | $164.61 | 300 | $49,383.00 | 22,185 | SEC Form 4 |
| Arif Bilal | SRPT | Chief Tech Ops Officer | Jun 21 '24 | Sell | $163.83 | 1,055 | $172,840.65 | 22,485 | SEC Form 4 |
| Arif Bilal | SRPT | Chief Tech Ops Officer | Jun 21 '24 | Sell | $162.31 | 5,580 | $905,689.80 | 23,540 | SEC Form 4 |
| Brown Ryan Edward | SRPT | EVP, General Counsel | Jun 21 '24 | Sell | $158.07 | 7,644 | $1,208,287.08 | 48,442 | SEC Form 4 |
| Brown Ryan Edward | SRPT | EVP, General Counsel | Jun 21 '24 | Sell | $159.14 | 2,200 | $350,108.00 | 46,242 | SEC Form 4 |
| Brown Ryan Edward | SRPT | EVP, General Counsel | Jun 21 '24 | Sell | $160.31 | 975 | $156,302.25 | 45,267 | SEC Form 4 |
| Brown Ryan Edward | SRPT | EVP, General Counsel | Jun 21 '24 | Sell | $161.82 | 4,168 | $674,465.76 | 41,099 | SEC Form 4 |
| Brown Ryan Edward | SRPT | EVP, General Counsel | Jun 21 '24 | Sell | $162.65 | 17,581 | $2,859,549.65 | 23,518 | SEC Form 4 |
| Brown Ryan Edward | SRPT | EVP, General Counsel | Jun 21 '24 | Sell | $163.53 | 3,840 | $627,955.20 | 19,678 | SEC Form 4 |
| Brown Ryan Edward | SRPT | EVP, General Counsel | Jun 21 '24 | Sell | $164.52 | 2,549 | $419,361.48 | 17,129 | SEC Form 4 |
| Murray Dallan | SRPT | Chief Customer Officer | May 2 '24 | Sell | $140.00 | 3,635 | $508,900.00 | 18,125 | SEC Form 4 |
| Boor Kathryn Jean | SRPT | Director | Mar 11 '24 | Sell | $122.93 | 761 | $93,549.73 | 7,516 | SEC Form 4 |
| Wigzell Hans Lennart Rudolf | SRPT | Director | Mar 8 '24 | Sell | $123.85 | 3,155 | $390,746.75 | 34,685 | SEC Form 4 |
| Wigzell Hans Lennart Rudolf | SRPT | Director | Mar 8 '24 | Sell | $123.10 | 11,745 | $1,445,809.50 | 22,940 | SEC Form 4 |
| Wigzell Hans Lennart Rudolf | SRPT | Director | Mar 8 '24 | Sell | $122.39 | 100 | $12,239.00 | 22,840 | SEC Form 4 |
| Mayo Stephen | SRPT | Director | Mar 5 '24 | Sell | $122.96 | 3,135 | $385,479.60 | 6,621 | SEC Form 4 |
| Arif Bilal | SRPT | Chief Tech Ops Officer | Mar 1 '24 | Sell | $128.58 | 1,543 | $198,398.94 | 27,293 | SEC Form 4 |
| Arif Bilal | SRPT | Chief Tech Ops Officer | Mar 1 '24 | Sell | $129.71 | 457 | $59,277.47 | 26,836 | SEC Form 4 |
| Brown Ryan Edward | SRPT | EVP, General Counsel | Mar 1 '24 | Sell | $125.34 | 2,000 | $250,680.00 | 31,827 | SEC Form 4 |
| Estepan Ian Michael | SRPT | Chief Financial Officer | Mar 1 '24 | Sell | $128.30 | 1,200 | $153,960.00 | 39,114 | SEC Form 4 |
| Barry Richard | SRPT | Director | Nov 3 '23 | Buy | $78.81 | 10,000 | $788,100.00 | 10,000 | SEC Form 4 |
| Barry Richard | SRPT | Director | Nov 3 '23 | Buy | $78.81 | 40,000 | $3,152,400.00 | 140,000 | SEC Form 4 |
Latest Sarepta Therapeutics Inc. (DE) News
SRPT Breaking Stock News: Dive into SRPT Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
SRPT: Rating decreased to a SELL
Moneywise
6 days ago
This market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likes
Zacks
7 days ago
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade
GlobeNewswire
9 days ago
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
Argus Research
10 days ago
SRPT: Raising target price to $156.00
Zacks
10 days ago
What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?
Argus Research
17 days ago
SRPT: Rating increased to a HOLD
Zacks
18 days ago
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
Compare SRPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRPT Sarepta Therapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.